MONTREAL, Oct. 20, 2005 (PRIMEZONE) -- Dr. Jean-Marie Dupuy, president of Viropro Inc. (OTCBB:VPRO) and affiliated companies, is pleased to announce the appointment of Patrick Daoust as director of the Bio-Generics Products Division of its subsidiary, Viropro Pharma Inc.
With this appointment, the company will be in a position to take advantage of Mr. Daoust's knowledge of recombinant protein development procedures and his scientific and industrial expertise in the area of technological transfer projects and training programs for Viropro Pharma Inc.'s international partners.
Mr. Daoust will be working closely with Dr. Octavian Gartu, director of technical operations (GMP), a specialist in the large-scale production of recombinant molecules (up-stream), and Dr. Patrick Benoist, special project manager with expertise mainly in purification processes (down-stream).
"I am delighted to be given this opportunity to work with the company's team of internationally known physicians and researchers in the field of molecular biotechnology, and to put my scientific and business experience to work for the company," said Mr. Daoust. "It will be our challenge to develop a solid portfolio of quality bio-generic products that, combined with winning strategies, will ensure us an enduring position on international markets and generate short-term revenue."
Patrick Daoust has more than five years experience in bioprocess development. Before coming to Viropro Pharma, he worked for ProMetic Life Sciences in the areas of business development and process management from 2002 to 2005. Because of his technical expertise in developing industrial cell lines, Mr. Daoust was subsequently assigned responsibility for the scientific coordination of bio-generic development. Mr. Daoust has an MSc in microbiology from the University of Montreal.
About Viropro, Inc.
Viropro, Inc. (OTCBB:VPRO) which conducts business through its operating subsidiary Viropro Pharma Inc. headquartered in Montreal, Canada is rapidly establishing a growth portfolio in the Life Sciences market through strategic alliances and revenue-producing acquisitions with the potential for continued shareholder value.
For more information on Viropro Pharma Inc., please visit our website on www.viropropharma.com
Viropro, Inc's Safe Harbor Statement
Except for any historic information contained herein, the matters discussed in this press release contain forward-looking statements that involve risks and uncertainties, which are subject to section 27A of the Securities Act of 1933 and section 21E of the Exchange Act of 1934, and are subject to safe harbor created by these sections. Any statements that express or involve discussions with respect to predictions, beliefs, plans, projections, objectives, goals, assumptions of future events or performances are not statements of historical fact and may be "forward looking statements". Forward looking statements in this release may be identified through the use of such words as "expects," "anticipates," "estimates," "believes," or statements indicating certain actions "may," "could," or "might" occur. Actual results, performance or achievements could differ materially from those anticipated in such forward-looking statements, which involve numerous risks and uncertainties, including the Company's ability to market its products and services in a competitive environment as well as other factors.